Objectives: Cytochrome P450 (CYP) 2C19 is expressed in vascular endothelium and metabolizes arachidonic acid to biologically active epoxyeicosatrienoic acids (EETs), which are potent endogenous vasodilators and inhibitors of vascular inflammation. The purpose of this study is to explore the relationship between the interaction of CYP2C19*3 polymorphism and smoking and coronary artery disease (CAD) in a Uighur population. Methods: In a Chinese Uighur case-control study of patients with CAD (n ¼ 336) and healthy controls (n ¼ 370), we investigated the roles of polymorphism in the CYP2C19 gene by the use of polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) analysis. Results: The CYP2C19*3 AG þ AA genotype was significantly more prevalent in patients with CAD (6.25.0% vs 2.96%; P ¼ .03). Multiple logistic regression analysis showed 4 independent risk factors: the interaction of CYP2C19*3 and smoking (OR 7.22, 95% confidence interval [CI] 2.32-10.23; P ¼ .009), smoking (OR 3.23, 95% CI 1.72-5.44; P ¼ .003), blood sugar (OR 2.12, 95% CI 1.03-4.21; P < .01), and hypertension (OR 1.74, 95% CI 0.98-2.34; P ¼ .013). Conclusions: The CYP2C19*3 polymorphism and CAD were synergistically and significantly associated in Chinese Uighur patients.
Introduction
Cytochrome P450 (CYP) epoxygenases metabolize arachidonic acid to epoxyeicosatrienoic acids (EETs). Current researches suggested that some CYP isoforms, such as CYP1A, 1 CYP2B, 2 CYP2C, 3 and CYP2D, 4 participate in arachidonic acid metabolism. One human CYP enzyme, CYP2C19, is abundantly expressed in coronary artery endothelial and smooth muscle cells and in cardiac myocytes 5, 6 and is the key enzyme of EET synthesis. The vasodilator properties of EETs have given rise to a hypothesis that they serve as endothelium-derived hyperpolarizing factor (EDHF), which contributes to the vasodilator response to acetylcholine and radykinin. Endothelium-derived hyperpolarizing factor could increase the expression and activity of the endothelial nitric oxide synthase (eNOS) and enhance the production of the nitric oxide. 7 More recently, the additional vascular protective effects of EETs, including antithrombotic, antimigratory, antioxidant, and antiapoptotic effects, have also been reported. 8, 9 Recently, a common genetic variant, CYP2C19*3 (CYP2C19 G636A) gene was associated with atherosclerosis 10 in some studies. This polymorphism, 636 G!A substitution in the exon 4 region, changes the tryptophan codon to the termination codon, which leads to the protein synthesis stopping earlier and the protein incompetency for the deficiency connective zone of the hemochrome and the substrate. However, the role of this gene variant in coronary artery disease (CAD) has not been sufficiently investigated.
Smoking is widely acknowledged as a major common environmental factor associated with the risk of CAD. 11 Smoking can disturb lipoprotein metabolism by increasing insulin resistance and lipid intolerance, and it is implicated in the production of small, dense low-density lipoprotein (LDL). [12] [13] [14] The smoking-associated risk of CAD has been reported to be greater in several genetic variants. [15] [16] [17] We hypothesized that those with the CYP2C19*3 may have a higher inflammatory status and, therefore, a higher risk of CAD. We also speculated that there should be a synergistic interaction between the effect of smoking and the genetic variation for the CAD.
Materials and Methods Participants
Participants diagnosed with CAD were recruited at the First Teaching Hospital of Xinjiang Medical University from 2005 to 2007. We enrolled 336 patients with CAD and 370 control participants in the current study. All patients and controls included in this study were Uighur Chinese from the same geographic area in Xinjiang. Demographic data and information about the presence of traditional coronary risk factors, including hypertension, diabetes mellitus, smoking, and serum cholesterol, were collected from all study participants.
Coronary artery disease was defined as the presence of at least 1 significant coronary artery stenosis of more than 50% luminal diameter on coronary angiography. Patients with ascertained congenital hypercoagulable status, with a proved disease-limiting life expectance, or with declared cocaine abuse were excluded. The control participants were selected from the volunteers who had been hospitalized from 2005 to 2007 for regular medical checkups and found to be healthy. Individuals were considered disease-free and therefore eligible as controls when their coronary arteries were angiographically normal and when they had no history of CAD, no symptoms suggestive of CAD, no electrocardiographic signs of CAD, no regional wall motion abnormalities, and no relevant valvular abnormalities in echocardiograms. 18 Coronary angiography in the control individuals was performed for the evaluation of chest pain. Control participants with CAD and any neoplasm, cardiomyopathy, or severe illness-limiting life expectance or refusing consent were excluded. Systemic arterial hypertension was defined as a systolic blood pressure (SBP) of !140 mm Hg and/or a diastolic blood pressure (DBP) of !90 mm Hg, 19 on at least 2 separate occasions, or antihypertensive treatment. Hypercholesterolemia was defined as a documented total cholesterol value !240 mg/dL (!6.2 mmol/L) or current treatment with cholesterol-lowering medication. Persons reporting regular smoking in the previous 6 months were considered current smokers. Persons who were drinking in the last 6 months were considered alcohol users. Diabetes mellitus was defined as the presence of an active treatment with insulin or an oral antidiabetic agent; for patients on dietary treatment, documentation of an abnormal fasting blood glucose or glucose tolerance test based on the World Health Organization criteria 20 was required for establishing this diagnosis. Informed consent was obtained from each individual according to a protocol approved by the Ethics Committee of the First Affiliated Hospital of Xinjiang Medical University.
Biochemical Analysis
The plasma concentrations of total cholesterol, triglyceride, and glucose and the serum concentration of uric acid were measured by standard methods in the Central Laboratory of First Affiliated Hospital of Xinjiang Medical University.
Sample DNA Extraction
Blood samples were collected with a standard venipuncture technique and EDTA-containing tubes. DNA was extracted from peripheral vein blood leukocytes using a whole blood genome extraction kit (Beijing Boiteke Corporation Beijing, China. http://bioteke.technew.cn).
Genotyping of CYP2C19*3 Polymorphism
Genotyping was confirmed by polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) analysis. The primer of CYP2C19 was designed by the Primer Premier 5.0 software. The forward primer is 5 0 -CATCCT GGGCTGTGCT-3 0 ; the reverse primer is 5 0 -AGGGCTTTG-GAGTTTAGTG-3 0 ; and annealing temperature is 52 C. The PCR product (15 mL) was incubated with BamHI (Fermentas Corporation Burlington, Canada) 5 U in a total volume of 25 mL overnight at 37 C, and the resulting fragments were separated on a 1.5% agarose gel. The presence of the G636A variant creates a BamHI site producing 2 fragments of 263 and 133 base pairs (bp; Figure 1A ). To ensure the results to be verified, we used sequenced genomic DNAs as positive controls in our assays ( Figure 1B) . 
Statistical Analysis
Data analysis was performed using the computer software Statistical Package for Social Sciences (SPSS) for Windows (version 13.0, SPSS Institute, Chicago, Illinois). Hardy-Weinberg equilibrium was assessed by chi-square analysis. Measurement data are shown as means + SD, and the differences between the patients with CAD and the control participants were assessed by independent sample t test. Differences in enumeration data between patients with CAD and control participants were analyzed using the chi-square test. Differences in distributions of genotypes and alleles between patients with CAD and control participants were analyzed using chi-square test. Allele frequencies distribution was analyzed by 2 Â 2 contingency tables using a 5% level of significance. Multiple logistic regression analysis was used to estimate the odds ratio (OR) and its 95% confidence interval (CI) as a measure of the association between polymorphism of CYP2C19 and risk of CAD.
Results

Comparison of Traditional CAD Risk Factors Between Patients With CAD and Controls
We compared patients with CAD and controls and for the traditional CAD risk factors (Table 1 ). There were no significant differences between patients with CAD and control participants in age, total cholesterol, triglyceride level, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and drinking (all P > .05), but there were significant differences in smoking, blood glucose, SBP, DBP, hypertension, apolipoprotein A, apolipoprotein B, and serum creatinine (all P < .05).
Distribution of the CYP2C19*3 Genotype
The frequency of the CYP2C19*3 A allele was significantly higher in patients with CAD than in controls (3.42% vs 1.49%; P ¼ .02). The CYP2C19*3 AG þ AA genotype was significantly more prevalent in patients with CAD (6.25% vs 2.70%; P ¼ .03, Table 2 ).
Identification of Independent Myocardial Infarction (MI) Risk Factors
In participants who did not smoke, the CYP2C19*3 A allele (AA or AG genotype) was not associated with an increased risk of CAD (OR ¼ 0.9, 95% CI: 0.4-1.1). Among participants carrying CYP2C19*3 GG genotypes, smoking history was associated with 2 times higher risk (OR ¼ 2.0, 95% CI: 1.2-3.4). However, smoking history and carrying CYP2C19*3 A allele (AA or AG genotype) would be associated with an 8.7-fold risk of CAD (OR ¼ 8.7, 95% CI: 2.58-10.23), when compared with nonsmoking CYP2C19*3 GG genotypes (Table 3) .
Multiple logistic regression analysis showed 4 independent risk factors: the interaction of CYP2C19*3 and smoking (OR ¼ 7.22, 95% CI: 2.32-10.10; P ¼ .009), smoking (OR ¼ 3.23, 95% CI: 1.72-5.44; P ¼ .003), blood sugar (OR ¼ 2.12, 95% CI: 1.03-4.21; P < .01), and hypertension (OR ¼ 1.74, 95% CI: 0.98-2.34; P ¼ .013). Moreover, there was a synergistic effect between smoking and the CYP2C19*3 and the occurrence of CAD (Table 4 ).
Limitation of This Study
The current study was limited by the relatively small sample size. This may have led to weak statistical significance and wide CIs when estimating ORs. The other study limitation is that we did not survey all the previously reported gene variations that might affect the metabolism of arachidonic acid and, therefore, contribute to the regulation of vascular tone.
Discussion
In this study, we found Chinese Uighur patients with CAD had a higher frequency of the CYP2C19*3 A allele than did controls. There was also significant synergism between this polymorphism and smoking for the CAD in Xinjiang, the West China. We found that patients with the CYP2C19*3 polymorphism have a higher possibility of CAD. This is consistent with the report 10 that the CYP2C19*3 mutant A allele changes the tryptophan codon to the termination codon, which results in the protein synthesis stopping earlier and the protein incompetency for the deficiency connective zone of the hemochrome and the substrate. Cytochrome P450 epoxygenases metabolize arachidonic acid to EETs. Some of the EETs are reported to have potential antiinflammatory or vasodilatation properties on the vasculature. [21] [22] [23] The additional antithrombotic, antimigratory, antioxidant, and antiapoptotic effects of EETs 24, 25 all help explain the possible vascular protection effect and the mechanism of CAD.
To our knowledge, we are the first to report this gene-environment interaction between smoking and the CYP2C19*3 polymorphism in Chinese Uighur population. Compared with the nonsmokers carrying CYP2C19*3 GG genotype, the GG genotype smoker was associated with a 2.0-fold risk of CAD. Interestingly, our interaction analysis showed that smoking could significantly increase a 7.7-fold risk in patients with CAD with the CYP2C19*3 A allele (AG þ AA), compared with nonsmoking patients with the CYP2C19*3 GG genotype.
Smoking may induce a hypercoagulable state by increasing platelet aggregability and has been recognized as a potent risk factor for CAD. 26 Smoking itself can alter some particular tumor progression via the signaling transduction and thus modify the EET metabolism. 27 Patients with CAD with both smoking behaviors and CYP2C19*3 genetic variation were expected to be more prone to oxidative stress damage. This effect derives not only from the impaired EET functions but also the possible influence from extract materials of the cigarettes, especially nicotine.
Previous study showed that some arachidonic acid metabolites, including some EETs, could induce coronary artery contractions by interference of an endothelium-derived relaxing factor release via production of some cyclooxygenase metabolites of arachidonic acid, 28 which could be also activated by nicotine. 29 Without some protective EETs for endothelium, like genetic variation in CYP2C19*3, the disturbance of the local circulation or vasoconstriction effect might be enhanced. As a result, it is also involved in the pathophysiology of cardiovascular immunoinflammatory diseases. Our finding needs further investigation to explain the mechanism of this gene-environment or other possible pharmacogenetic interactions.
Conclusions
We found a significant association between the CYP2C19*3 polymorphism and CAD in Chinese Uighur people. The interaction between CYP2C19*3 polymorphism and smoking was an independent risk factor for CAD. 
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